Beam Therapeutics Inc
BEAM25.030USD
+0.340+1.38%
Close 11/26, 16:00（ET）Quotes delayed by 15 min
2.54BMarket Cap
LossP/E TTM
More Details of Beam Therapeutics Inc Company
Beam Therapeutics Inc. is a biotechnology company developing precision genetic medicines through base editing. The Company's suite of gene editing technologies is anchored by base editing, a technology that is designed to enable precise, predictable and efficient single base changes, at targeted genomic sequences, without making double-stranded breaks in the deoxyribonucleic acid. Its lead programs are focused on sickle cell disease and alpha-1 antitrypsin deficiency, and it is also advancing programs in other genetic diseases, as well as immunology/oncology. Its primary programs include BEAM-101, Engineered Stem Cell Antibody Paired Evasion (ESCAPE), BEAM-302, BEAM-301 and BEAM-201. BEAM-101 is a patient-specific, autologous hematopoietic stem cell (HSC), investigational therapy. ESCAPE is a potentially non-genotoxic approach to HSC transplantation. BEAM-302 is a liver-targeting lipid nanoparticle formulation of base editing reagents. BEAM-201 is an anti-CD7 CAR-T product candidate.
Beam Therapeutics Inc Info
Ticker SymbolBEAM
Company nameBeam Therapeutics Inc
IPO dateFeb 06, 2020
CEOMr. John M. Evans
Number of employees483
Security typeOrdinary Share
Fiscal year-endFeb 06
Address238 Main Street
CityCAMBRIDGE
Stock exchangeNASDAQ Global Select Consolidated
CountryUnited States of America
Postal code02142
Phone18573278775
Websitehttps://beamtx.com/
Ticker SymbolBEAM
IPO dateFeb 06, 2020
CEOMr. John M. Evans
Company Executives of Beam Therapeutics Inc
Name
Name/Position
Position
Shareholding
Change
Dr. Giuseppe Ciaramella, Ph.D.
Dr. Giuseppe Ciaramella, Ph.D.
President
President
107.78K
-6.45%
Dr. Amy Simon, M.D.
Dr. Amy Simon, M.D.
Chief Medical Officer
Chief Medical Officer
1.74K
-97.47%
Dr. John M. Maraganore, Ph.D.
Dr. John M. Maraganore, Ph.D.
Independent Director
Independent Director
--
--
Dr. Christine P. Bellon, Ph.D.
Dr. Christine P. Bellon, Ph.D.
Chief Legal Officer and Secretary
Chief Legal Officer and Secretary
--
--
Mr. Sravan K. Emany
Mr. Sravan K. Emany
Chief Financial and Principal Financial Officer
Chief Financial and Principal Financial Officer
--
--
Mr. John M. Evans
Mr. John M. Evans
Chief Executive Officer, Principal Accounting Officer, Director
Chief Executive Officer, Principal Accounting Officer, Director
--
--
Mr. Chirfi Guindo
Mr. Chirfi Guindo
Independent Director
Independent Director
--
--
Ms. Christi Shaw
Ms. Christi Shaw
Independent Director
Independent Director
--
--
Dr. Mark C. Fishman, M.D.
Dr. Mark C. Fishman, M.D.
Lead Independent Director
Lead Independent Director
--
--
Mr. Graham K. Cooper
Mr. Graham K. Cooper
Independent Director
Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Giuseppe Ciaramella, Ph.D.
Dr. Giuseppe Ciaramella, Ph.D.
President
President
107.78K
-6.45%
Dr. Amy Simon, M.D.
Dr. Amy Simon, M.D.
Chief Medical Officer
Chief Medical Officer
1.74K
-97.47%
Dr. John M. Maraganore, Ph.D.
Dr. John M. Maraganore, Ph.D.
Independent Director
Independent Director
--
--
Dr. Christine P. Bellon, Ph.D.
Dr. Christine P. Bellon, Ph.D.
Chief Legal Officer and Secretary
Chief Legal Officer and Secretary
--
--
Mr. Sravan K. Emany
Mr. Sravan K. Emany
Chief Financial and Principal Financial Officer
Chief Financial and Principal Financial Officer
--
--
Mr. John M. Evans
Mr. John M. Evans
Chief Executive Officer, Principal Accounting Officer, Director
Chief Executive Officer, Principal Accounting Officer, Director
--
--
Revenue Breakdown
FY2025Q2
FY2025Q1
FY2024
FY2023
FY2022
FY2021
FY2020
FY2019
Relevant data have not been disclosed by the company yet.
By RegionUSD
Name
Revenue
Proportion
United States
8.47M
0.00%
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Sun, Nov 16
Updated: Sun, Nov 16
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Fidelity Management & Research Company LLC
11.11%
ARK Investment Management LLC
10.88%
Farallon Capital Management, L.L.C.
9.92%
The Vanguard Group, Inc.
9.09%
BlackRock Institutional Trust Company, N.A.
6.68%
Other
52.33%
Shareholders
Shareholders
Proportion
Fidelity Management & Research Company LLC
11.11%
ARK Investment Management LLC
10.88%
Farallon Capital Management, L.L.C.
9.92%
The Vanguard Group, Inc.
9.09%
BlackRock Institutional Trust Company, N.A.
6.68%
Other
52.33%
Shareholder Types
Shareholders
Proportion
Investment Advisor
56.24%
Investment Advisor/Hedge Fund
20.11%
Hedge Fund
16.85%
Venture Capital
4.79%
Research Firm
2.41%
Individual Investor
1.27%
Bank and Trust
1.22%
Pension Fund
0.28%
Family Office
0.06%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
539
106.16M
104.63%
-429.74K
2025Q2
537
101.17M
100.03%
+11.84M
2025Q1
562
100.13M
99.59%
+12.37M
2024Q4
542
80.18M
95.83%
-6.23M
2024Q3
539
78.60M
95.42%
-7.95M
2024Q2
538
78.23M
95.09%
-5.21M
2024Q1
550
76.09M
93.23%
-4.97M
2023Q4
549
75.48M
92.79%
-3.23M
2023Q3
554
74.84M
95.14%
-3.35M
2023Q2
566
72.06M
94.81%
-2.24M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Fidelity Management & Research Company LLC
12.53M
12.38%
+4.93M
+64.83%
Jun 30, 2025
ARK Investment Management LLC
10.41M
10.29%
+1.56M
+17.66%
Jul 31, 2025
Farallon Capital Management, L.L.C.
10.01M
9.9%
+85.00K
+0.86%
Jun 30, 2025
The Vanguard Group, Inc.
9.69M
9.58%
+837.64K
+9.47%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
6.72M
6.64%
-37.63K
-0.56%
Jun 30, 2025
Amova Asset Management Co., Ltd.
4.73M
4.68%
+462.57K
+10.84%
Jun 30, 2025
ARCH Venture Partners
4.54M
4.49%
--
--
Jun 30, 2025
State Street Investment Management (US)
3.64M
3.6%
+198.15K
+5.76%
Jun 30, 2025
Bellevue Asset Management AG
2.89M
2.86%
+493.36K
+20.59%
Jun 30, 2025
Kynam Capital Management LP
2.42M
2.39%
-100.52K
-3.99%
Jun 30, 2025
View more
Related ETFs
Updated: Thu, Nov 6
Updated: Thu, Nov 6
Name
Proportion
ARK Genomic Revolution ETF
4.11%
ARK Innovation ETF
2.75%
Global X Genomics & Biotechnology ETF
2.43%
WisdomTree BioRevolution Fund
2.24%
Virtus LifeSci Biotech Clinical Trials ETF
1%
Franklin Genomic Advancements ETF
0.91%
SPDR S&P Biotech ETF
0.85%
Harbor Health Care ETF
0.51%
Direxion Daily S&P Biotech Bull 3X Shares
0.45%
Invesco Nasdaq Biotechnology ETF
0.25%
View more
ARK Genomic Revolution ETF
Proportion4.11%
ARK Innovation ETF
Proportion2.75%
Global X Genomics & Biotechnology ETF
Proportion2.43%
WisdomTree BioRevolution Fund
Proportion2.24%
Virtus LifeSci Biotech Clinical Trials ETF
Proportion1%
Franklin Genomic Advancements ETF
Proportion0.91%
SPDR S&P Biotech ETF
Proportion0.85%
Harbor Health Care ETF
Proportion0.51%
Direxion Daily S&P Biotech Bull 3X Shares
Proportion0.45%
Invesco Nasdaq Biotechnology ETF
Proportion0.25%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Beam Therapeutics Inc?
The top five shareholders of Beam Therapeutics Inc are:
Fidelity Management & Research Company LLC holds 12.53M shares, accounting for 12.38% of the total shares.
ARK Investment Management LLC holds 10.41M shares, accounting for 10.29% of the total shares.
Farallon Capital Management, L.L.C. holds 10.01M shares, accounting for 9.90% of the total shares.
The Vanguard Group, Inc. holds 9.69M shares, accounting for 9.58% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 6.72M shares, accounting for 6.64% of the total shares.
Fidelity Management & Research Company LLC holds 12.53M shares, accounting for 12.38% of the total shares.
ARK Investment Management LLC holds 10.41M shares, accounting for 10.29% of the total shares.
Farallon Capital Management, L.L.C. holds 10.01M shares, accounting for 9.90% of the total shares.
The Vanguard Group, Inc. holds 9.69M shares, accounting for 9.58% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 6.72M shares, accounting for 6.64% of the total shares.
What are the top three shareholder types of Beam Therapeutics Inc?
The top three shareholder types of Beam Therapeutics Inc are:
Fidelity Management & Research Company LLC
ARK Investment Management LLC
Farallon Capital Management, L.L.C.
Fidelity Management & Research Company LLC
ARK Investment Management LLC
Farallon Capital Management, L.L.C.
How many institutions hold shares of Beam Therapeutics Inc (BEAM)?
As of 2025Q3, 539 institutions hold shares of Beam Therapeutics Inc, with a combined market value of approximately 106.16M, accounting for 104.63% of the total shares. Compared to 2025Q2, institutional shareholding has increased by 4.60%.
What is the biggest source of revenue for Beam Therapeutics Inc?
In FY2025Q2, the -- business generated the highest revenue for Beam Therapeutics Inc, amounting to -- and accounting for --% of total revenue.
